GlassScriptPhysician profile
Malkan Pilipovic
NPI 1356034532
$4,656.21
in general payments reported to CMS, 2019-2025
22 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $232 · 2024: $2,014 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,614 · Education: $41.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,614.34 |
| Education | $41.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $907.81 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $621.38 | 2023-2025 | Caplyta |
| Abbvie INC. | $518.16 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $457.71 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $415.32 | 2023-2025 | Rexulti |
| Corium, LLC | $303.72 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $232.93 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $216.43 | 2023-2025 | Auvelity |
| Alkermes, INC. | $192.05 | 2024-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $169.29 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $126.21 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $124.61 | 2024-2025 | Ingrezza |
| Noven Therapeutics, LLC | $96.61 | 2024-2025 | Xelstrym, Secuado |
| Itamar Medical INC | $53.62 | 2024-2025 | Watchpatone |
| Neos Therapeutics, LP | $52.63 | 2024-2025 | Adzenys Xr-Odt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.47 | 2024-2025 | Trintellix |
| Tris Pharma INC | $28.34 | 2024-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $27.75 | 2024 | Loreev Xr |
| Mdd US Operations, LLC | $22.76 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $19.51 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.44 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $13.46 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malkan Pilipovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.